Critical IllnessNCT07888010
Dynamic Inflammatory Changes and Nutritional Risk Scores in ICU Patients Aged 65 Years and Older
An observational study of Critical Illness and Geriatric Patient, run by Ankara Etlik City Hospital at 1 site in Turkey (Türkiye).
Trial summary
"This prospective observational study aims to evaluate the prognostic value of dynamic changes in the serum uric acid-to-albumin ratio (UAR) measured on admission (Day 0) and on Day 3, along with mNUTRIC and PNI scores, regarding 28-day mortality in intensive care patients aged 65 and older." Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Critical Illness, Geriatric Patient, Mortality
- What is being tested?
- Uric Acid to Albumin Ratio (UAR) and Nutritional Risk Scores
- How many people
- 224 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Nov 2026to 1 Jun 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: Patients aged 65 and older who were admitted to the intensive care units of Ankara Etlik City Hospital and followed for at least 72 hours.
Who may be able to join
- Being 65 years of age or older
- Having been followed up in the intensive care unit for at least 72 hours
- Provision of written informed consent from the patient or their legal representative
Who cannot join
- Patients with terminal-stage malignancy
- Chronic kidney disease of KDIGO stage 4 or higher
- End-stage liver disease
- Active hematological malignancy
- Patients receiving immunosuppressive therapy
- Patients with an active gout attack or using uric acid-lowering therapy
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site
Ankara Etlik City Hospital
Ankara
saniye kozan, +905396650985, saniyekoymen@hotmail.com
About this study
Official title: "The Effect of Dynamic Inflammatory Changes and Nutritional Risk Scores on Mortality in Intensive Care Patients Aged 65 Years and Older"
"This prospective observational study aims to evaluate the prognostic value of dynamic changes in the serum uric acid-to-albumin ratio (UAR) measured on admission (Day 0) and on Day 3, along with mNUTRIC and PNI scores, regarding 28-day mortality in intensive care patients aged 65 and older."
Read the detailed description
"As the elderly population in intensive care units (ICUs) continues to grow, identifying reliable and accessible prognostic markers for mortality becomes increasingly critical. This study is designed as a single-center, prospective observational cohort study conducted at Ankara Etlik City Hospital. A total of 224 patients aged 65 and older who stay in the ICU for at least 72 hours will be evaluated.
The primary objective is to investigate whether the dynamic changes in the Uric Acid-to-Albumin Ratio (UAR) between admission and the 3rd day of ICU stay-combined with nutritional and clinical risk scores such as mNUTRIC, PNI, APACHE II, and SOFA-can reliably predict 28-day all-cause mortality. Laboratory parameters, routine biochemistry, hemogram, and clinical outcomes including mechanical ventilation duration and total ICU length of stay will be systematically recorded."
- Conditions
- Critical Illness, Geriatric Patient, Mortality, Inflamation
- Being tested
- Uric Acid to Albumin Ratio (UAR) and Nutritional Risk Scores
- Keywords
- Intensive care, mNUTRIC, Prognostic nutritional index, Uric acid to albumin ratio
- Medical subject headings
- Critical Illness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Uric Acid to Albumin Ratio (UAR) and Nutritional Risk ScoresOther
Observational evaluation of biomarkers and clinical scores.
| Study group | Role | What they receive |
|---|---|---|
| Elderly ICU Patients | Patients aged 65 and older who were hospitalized in the intensive care unit for at least 72 hours Receives: Other: Uric Acid to Albumin Ratio (UAR) and Nutritional Risk Scores |
What is being measured
The primary outcome is the main question the study is designed to answer.
28-day Mortality
All-cause mortality evaluated up to 28 days following intensive care unit admission, and its prognostic relationship with the dynamic changes in serum uric acid-to-albumin ratio (UAR) between admission and Day 3, along with baseline mNUTRIC and PNI scores.
Measured: 28 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Oct 2026
- Study start1 Nov 2026 (estimated)
- Primary completion1 Jun 2027 (estimated)
- Study completion1 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Critical IllnessStudies of the same condition, open and under way.
- More trials run by Ankara Etlik City HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 224 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ankara Etlik City Hospital
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Saniye Kozan, Ankara Etlik City Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07888010
- Sponsor's protocol ID
- AEŞH-EK-2026-167
- Status last verified
- Oct 2026
- First submitted
- 15 Oct 2026
- Last updated
- 26 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Individual participant data will not be shared due to institutional data privacy regulations and ethical restrictions regarding patient confidentiality.
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- "The Effect of Dynamic Inflammatory Changes and Nutritional Risk Scores on Mortality in Intensive Care Patients Aged 65 Years and Older"
- ClinicalTrials.gov ID
- NCT07888010
- Acronym / sponsor ID
- AEŞH-EK-2026-167
- Conditions
- Critical Illness, Geriatric Patient, Mortality, Inflamation
- Keywords
- Intensive care, mNUTRIC, Prognostic nutritional index, Uric acid to albumin ratio
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 224 participants (estimated)
- Lead sponsor
- Ankara Etlik City HospitalOther government
- Study start
- 1 Nov 2026 (estimated)
- Primary completion
- 1 Jun 2027 (estimated)
- Study completion
- 1 Jun 2027 (estimated)
- First posted
- 22 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
"This prospective observational study aims to evaluate the prognostic value of dynamic changes in the serum uric acid-to-albumin ratio (UAR) measured on admission (Day 0) and on Day 3, along with mNUTRIC and PNI scores, regarding 28-day mortality in intensive care patients aged 65 and older."
Detailed description
"As the elderly population in intensive care units (ICUs) continues to grow, identifying reliable and accessible prognostic markers for mortality becomes increasingly critical. This study is designed as a single-center, prospective observational cohort study conducted at Ankara Etlik City Hospital. A total of 224 patients aged 65 and older who stay in the ICU for at least 72 hours will be evaluated.
The primary objective is to investigate whether the dynamic changes in the Uric Acid-to-Albumin Ratio (UAR) between admission and the 3rd day of ICU stay-combined with nutritional and clinical risk scores such as mNUTRIC, PNI, APACHE II, and SOFA-can reliably predict 28-day all-cause mortality. Laboratory parameters, routine biochemistry, hemogram, and clinical outcomes including mechanical ventilation duration and total ICU length of stay will be systematically recorded."
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Elderly ICU Patients | – | Other: Uric Acid to Albumin Ratio (UAR) and Nutritional Risk ScoresPatients aged 65 and older who were hospitalized in the intensive care unit for at least 72 hours |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- Patients aged 65 and older who were admitted to the intensive care units of Ankara Etlik City Hospital and followed for at least 72 hours.
Key inclusion criteria (3 listed)
- Being 65 years of age or older
- Having been followed up in the intensive care unit for at least 72 hours
- Provision of written informed consent from the patient or their legal representative
Key exclusion criteria (6 listed)
- Patients with terminal-stage malignancy
- Chronic kidney disease of KDIGO stage 4 or higher
- End-stage liver disease
- Active hematological malignancy
- Patients receiving immunosuppressive therapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Uric Acid to Albumin Ratio (UAR) and Nutritional Risk ScoresObservational evaluation of biomarkers and clinical scores. | Other | Elderly ICU Patients |
Primary outcome
28-day Mortality
Time frame: 28 days
All-cause mortality evaluated up to 28 days following intensive care unit admission, and its prognostic relationship with the dynamic changes in serum uric acid-to-albumin ratio (UAR) between admission and Day 3, along with baseline mNUTRIC and PNI scores.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2026.
- Individual participant dataSharing planned: Undecided. Individual participant data will not be shared due to institutional data privacy regulations and ethical restrictions regarding patient confidentiality.
Related trials for Critical Illness
RecruitingPhase 4
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Infection, Sepsis
Recruiting
Development and Preliminary Validation of Intelligent Video Laryngoscope for Emergency Use
Critically Ill Patients Requiring Mechanical Ventilation
Active, not recruiting
Weighted Blankets for Agitation in Adults in the Intensive Care Unit
Psychomotor Agitation, Critical Illness
Not yet recruitingObservational study
Core Competencies in General Intensive Care Ultrasound (GenIUS): a Delphi Study
Critical Illness, Ultrasound
RecruitingObservational study
Predicting Extubation Failure Using Machine Learning
Extubation Failure, Critical Illness
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Critical Illness and Geriatric Patient, run by Ankara Etlik City Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 26 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact saniye kozan, Research Assistant (+905396650985, saniyekoymen@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
28-day Mortality (time frame: 28 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2026.